Vitalograph and Thorasys forge strategic partnership to expand respiratory diagnostics with launch of tremoflo® C2 oscillometer

At the American Thoracic Society (ATS) Annual Conference, Vitalograph and Thorasys announced a strategic partnership that further integrates oscillometry technology into Vitalograph’s respiratory diagnostics portfolio.

• The partnership marks the official launch of the tremoflo® C2 portable oscillometer in the United States, broadening access to Airwave Oscillometry System (AOS) technology for diverse patient groups.

• Vitalograph’s customers in the U.S. will now benefit from fully integrated oscillometry as part of their comprehensive respiratory diagnostics range.

Pictured at the launch of the tremoflo C2 oscillometer at ATS 2025: Christian Gossmann, Managing Director of Thorasys GMBH and VP of Global Business Development, Frank Keane, CEO Vitalograph, Doreen Miao, Vice President, Marketing and Clinical Trial Services, Thorasys, and Gareth Morgan, President Morgan Scientific

This partnership marks a significant step forward in making advanced respiratory diagnostics more accessible and integrated for healthcare providers and their patients.

Doreen Miao, Vice President of Marketing and Strategic Development at Thorasys, commented: “We are thrilled to launch the tremoflo® C2, our second-generation clinical oscillometry solution, a vital enhancement to PFT testing. Oscillometry facilitates early detection, frequent monitoring and treatment optimization for a broad range of respiratory diseases. And because it’s effort-free testing, it is especially beneficial for patients who find spirometry challenging.”

Seamless Integration for U.S. Respiratory Healthcare Providers

The Thorasys partnership enables Morgan Scientific, Vitalograph’s U.S. entity specializing in pulmonary function testing (PFT) solutions, to offer oscillometry alongside its established suite of respiratory diagnostics. This integration ensures that oscillometry becomes a routine part of respiratory care, enabled by Morgan Scientific’s specialized team and the enterprise-level comPAS2 software from Vitalograph.

Gareth Morgan, President of Morgan Scientific, said: “Integrating oscillometry into our diagnostics portfolio is a significant advancement for clients whose patients have difficulty with spirometry. We are proud to be the first to offer the compact tremoflo® C2 oscillometer, fully integrated with our existing testing solutions.”

Driving Innovation and Research in Respiratory Health

This collaboration strengthens the foundation for ongoing research and development in oscillometry, enhancing the ability of healthcare professionals to diagnose and monitor lung diseases. The addition of the tremoflo® C2, alongside the tremoflo® C-100 oscillometer, to Vitalograph’s portfolio of diagnostic solutions offers healthcare providers the most comprehensive range of testing options available, supporting a more complete understanding of patient lung health.